Changes coming to U.S. import regulations, effective August 29th, 2025. All shipments may be affected. Read more for continued updates.
(Upadacitinib)
Prescription required. Can not be split. Product of Ireland. Shipped from Australia.
Prescription required. Can not be split. Product of Ireland. Shipped from Australia.
Rinvoq (upadacitinib) is an oral Janus kinase (JAK) inhibitor used to treat various chronic inflammatory and autoimmune diseases. By targeting specific enzymes involved in immune response, Rinvoq reduces inflammation and helps control symptoms in conditions like rheumatoid arthritis, atopic dermatitis, and inflammatory bowel disease. It is available as extended-release tablets and as a liquid formulation (Rinvoq LQ) for pediatric use.
Rheumatoid Arthritis (RA): For adults with moderate to severe progression of RA who have not responded to one or more TNF inhibitors.
Psoriatic Arthritis (PsA): For adults and children aged 2 years and older with inadequate response or intolerance to TNF inhibitors.
Atopic Dermatitis: For adults and children aged 12 years and older with moderate-to-severe eczema not controlled with other treatments.
Ulcerative Colitis (UC): For adults with moderate-to-severe UC that is inadequately controlled by TNF inhibitors.
Crohn’s Disease (CD): For adults with moderate-to-severe CD inadequately controlled by TNF inhibitors.
Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis: For adults unresponsive to TNF inhibitors.
Giant Cell Arteritis: For adults, often in combination with corticosteroids.
Polyarticular Juvenile Idiopathic Arthritis (JIA): For children aged 2 years and older.
To comply with Canadian International Pharmacy Association regulations you are permitted to order a 3-month supply or the closest package size available based on your personal prescription. read more
Rinvoq works by inhibiting JAK enzymes that trigger the body’s inflammatory responses. It is commonly prescribed to:
Control chronic inflammation
Reduce joint and skin symptoms
Improve gut health in IBD (UC and Crohn’s)
Help patients reduce reliance on systemic corticosteroids
Rinvoq is especially beneficial for patients who have not responded to or tolerated TNF blockers or biologic therapies.
Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Giant Cell Arthritis:
Adults: 15 mg once daily
Children: Dosed based on weight for ages 2 and older, depnding on the managed condition
Atopic Dermatitis:
Adults <65: Start with 15 mg once daily, may increase to 30 mg
Adults ≥65: 15 mg once daily
Adolescents ≥12 years: Weight-based dosing
Ulcerative Colitis:
Adults: 45 mg once daily for 8 weeks for induction
Adults: 15 mg or 30 mg once daily ongoing for maintenance
Crohn’s Disease:
Adults: 45 mg once daily for 12 weeks for induction
Adults: 15 mg or 30 mg once daily ongoing for maintenance
Juvenile Idiopathic Arthritis:
Weight-based dosing for ages 2+
Take Rinvoq tablets whole with or without food. Do not crush, chew, or split.
Take as soon as remembered unless near the time for your next dose. Do not double up.
Call Poison Control (1-800-222-1222) in the US or 1-844-764-7669 in Canada, or seek emergency care immediately.
Because Rinvoq is a potent immunosuppressant, the primary concern is an increased risk of infection.
Cold or flu symptoms
Acne, rash, or skin infections
Fatigue
Muscle pain
Elevated liver enzymes
Headache
Blood disorders (low red/white cells)
Severe infections: Shingles, pneumonia, TB, UTIs
Cardiovascular events: Heart attack, stroke
Blood clots: Deep vein thrombosis (DVT), pulmonary embolism
Cancers: Lymphoma, skin cancer, others
GI perforation: Abdominal pain, fever, vomiting blood
Retinal detachment: Sudden vision changes
Allergic reactions: Swelling, rash, trouble breathing
You are allergic to upadacitinib or any ingredient in the medication.
You are using another JAK inhibitor, biologic DMARD, or strong immunosuppressant unless directed by your doctor.
History of serious infections or TB
Cardiovascular risk (stroke, heart disease)
Cancer history
Liver or kidney impairment
GI conditions (e.g., ulcers, diverticulitis)
It’s important to have a thorough discussion of your complete medical history with your healthcare providers before starting Rinvoq.
Before starting, your healthcare provider is likely to recommend completing any recommended vaccinations. Once Rinvoq is started, vaccinations may become less effective due to a diminished immune response. A tuberculosis skin test and baseline blood tests are also recommended.
Not recommended during pregnancy; use effective birth control during and for 4 weeks after final dose.
Do not breastfeed while using Rinvoq or for 6 days after your last dose.
Pregnancy registry: Call 800-633-9110 to report exposure.
Tablets: Store between 36°F and 77°F (2°C to 25°C) in the original container.
Rinvoq LQ (liquid): Store between 36°F and 86°F (2°C to 30°C); discard 60 days after opening.
Grapefruit products: May increase drug concentration
Live vaccines: Increases infection risk
Other JAK inhibitors or immunosuppressants: Higher risk of infections or adverse effects
Antifungals: Ketoconazole, itraconazole, etc.
Antibiotics: Clarithromycin, rifampin
Seizure medications: Phenytoin
NSAIDs and steroids: May increase GI risks
Other immune modulators: Methotrexate, cyclosporine, biologics like Humira or Stelara
Always disclose all medications and supplements to your healthcare provider before starting Rinvoq.
The content on this page is for informational and educational purposes only and does not constitute professional medical advice. Patients should not use the information presented on this page for diagnosing a health-related issue or disease. Before taking any medication or supplements, patients should always consult a physician or qualified healthcare professional for medical advice or information about whether a drug is safe, appropriate or effective.
